Sen-Jam Pharmaceutical has reached a significant milestone by completing the enrollment for the Phase 2 clinical trial of its therapeutic, SJP-002C, designed to treat Upper Respiratory Infections (URIs) and COVID. The trial, conducted in collaboration with Duke University, successfully enrolled 150 participants, a target that was met after expanding recruitment efforts to additional sites. This achievement underscores Sen-Jam's commitment to advancing research in the fight against respiratory infections.
Key Highlights:
- Full Enrollment Achieved: The trial protocol required 150 participants, a goal that was met after initial recruitment challenges. By opening two additional sites, Sen-Jam was able to recruit 135 participants within five months.
- Safety Profile: To date, SJP-002C has not been associated with any serious side effects, highlighting its potential safety as a therapeutic option.
- Mechanism of Action: SJP-002C functions as a multi-targeted anti-inflammatory with antiviral properties, effective against various viral strains. This makes it a promising option for reducing symptoms and preventing the progression of respiratory infections to more severe conditions like pneumonia and cytokine storm.
- Manufacturing Plans: Partner KVK-Tech is scheduled to submit FDA manufacturing batches by Q4-2024, aiming to offer the treatment at a lower cost than existing options, thereby making it accessible to a broader patient population.
Sen-Jam Pharmaceutical is now looking forward to the next steps, including seeking FDA approval to commence Phase 3 clinical trials. The company is also actively seeking investment partners and strategic collaborations to support the further development and global commercialization of SJP-002C. With its innovative approach to treating inflammation and respiratory infections, Sen-Jam Pharmaceutical is poised to make a significant impact on global health.
